Theravance Biopharma, Inc. (TBPH) — Who's Buying and Selling (13F, Q2 2026)

TBPH ranks #3231 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

TBPH is a top-conviction position for Newtyn Management, LLC — at 7.3% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in TBPH belongs to Madison Avenue Partners, LP, but the position matters far more to Newtyn Management, LLC, who has 7.3% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

TBPH is down 0% today, but institutions show net buying of $13.7M this quarter — a divergence between today's price move and the underlying institutional flow.

TBPH posted net income of $53.8M over the trailing twelve months, and currently trades at a P/E of 16.3.

• Profitable — net income of $53.8M over the trailing twelve months
• Revenue grew 35.1% year over year
• Net income improved year over year, from $13.0M to $53.8M
• Generated $238.5M in positive operating cash flow
• Current ratio of 10.93x — enough short-term assets to cover short-term liabilities
• Liabilities run x equity — a highly leveraged balance sheet worth noting